Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice

British Journal of Cancer

Volumn 89, Issue 12, 2003, Pages 2219-2226

  Koedoot, C G ^a   De Haan, R J ^a   Stiggelbout, A M ^b   Stalmeier, P F M ^a   De Graeff, A ^c   Bakker, P J M ^a   De Haes, J C J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Best supportive care; Decision making; Palliative chemotherapy; Treatment choice; Treatment preference

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ATTITUDE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; COMPARATIVE STUDY; CONSULTATION; DECISION MAKING; DEMOGRAPHY; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; METASTASIS; METHODOLOGY; NEOPLASM; PALLIATIVE THERAPY; PATHOLOGY; PATIENT; PATIENT CARE; PATIENT EDUCATION; PATIENT SATISFACTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SOCIAL ASPECT; TERMINAL CARE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHOICE BEHAVIOR; EPIDEMIOLOGIC FACTORS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PALLIATIVE CARE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; TERMINAL CARE;

EID: 0842287228     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601445     Document Type: Article

References (51)

1. Barras JM, Sancez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JLL, Esponas JA, Germa JR (2001) Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ 322: 1-5
2. Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB (1988) Information and decision-making preferences of hospitalized adult cancer patients. Soc Sci Med 27: 11 1139-45
3. Brundage MD, Davidson JR, Mackillop WJ (1997) Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 15: 330-340
4. Cassileth BR, Zupkis RV, Sutton-smith K, March V (1980) Information and participation preferences among cancer patients. Ann Intern Med 92: 832-836
5. Charles C, Redko C, Whelan T, Gafni A, Reyno L (1998) Doing nothing is no choice: lay constructions of treatment decision-making among women with early-stage breast cancer. Sociol Health Illness 20(1): 75-95
6. Charles C, Gafni A, Whelan T (1999) Decision making in the physician-patient encounter: revisiting the shared decision making model. Soc Sci Med 49: 651-661
7. Degner LF, Sloan JA (1992) Decision making during serious illness: what role do patients really want to play? J Clin Epidemiol 45: 941-950
8. De Haes JCJM, Knippenberg FCE, Neijt JP (1990) Measuring psychological and physical distress in cancer patients: structure and applications of the Rotterdam symptom checklist. Br J Cancer 62: 1034-1038
9. De Haes JCJM, Koedoot CG (2003) Patient centered decision making in palliative cancer therapy: a world of paradoxes. Pat Edu Counsel 50: 43-49
10. Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19(5): 1266-1274
11. Dutch Cancer Foundation (1999), Signaleringsrapport 1999, deelrapport zorg. Amsterdam, The Netherlands
12. Flood AB, Wennberg JE, Nease RF, Fowler FJ, Ding J, Hynes LM (1996) The importance of patient preference in the decision to screen for prostate cancer. J Gen Intern Med 11: 342-349
13. Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafström L, Haglund U, Hägberg T, Janunger KG, Jönsson PE, Karlsson G, Kimby E, Lamnevik G, Nilsson S, Permeat J, Ragnhammar P, Sörenson S, Mygron P (2001) The Swedish council on technology assessment in health care (SBU) systematic overview of chemotherapy effects in some major tumour types - summary and conclusions. Acta Oncol 40: 135-154
14. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18(12): 2395-2405
15. Jansen SJT, Kievit J, Nooij MA, de Haes JCJM, Overpelt IME, van Slooten H, Maartense E, Stiggelbout AM (2001) Patients preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer 84(12): 1577-1585
16. Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In Evaluation of Chemotherapeutic Agents, MacLeod CM (ed) pp 191-205. New York: Colombia University Press
17. Kiebert GM, Stiggelbout AM, Kievit J, Leer JWH, van de Velde CJH, de Haes JCJM (1994) Choices in oncology factors that influence patients' treatment preference. Qual Life Res 3: 175-182
18. Koedoot CG, Varekamp I, Graeff de A, Bakker PJM, de Haes JCJM (1996) Do patients feel they have a choice concerning palliative chemotherapy. Psycho-Oncology 5(2): 174-175, (abstract)
19. Koedoot CG, de Haes JCJM, Heisterkamp SH, Bakker PJM, de Graeff A, de Haan RJ (2002) Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol 17: 3658-3664
20. Lindley C, Vasa S, Sawyer WT, Winer EP (1998) Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol 16(4): 1380-1387
21. Llewellyn-Thomas HA, McGreal MJ, Thiel EC (1995) Cancer patients' decision making and trial entry preferences: the effect of 'framing' information about short term toxicity and long term survival. Med Decision Making 15: 4-12
22. Maher EJ, Coia L, Duncan G, Lawton PA (1992) Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Biol Phys 23: 239-244
23. Mazur DJ, Hickam DH (1997) The influence of physician explanations on patient preferences about future health-care states. Med Decision Making 17: 56-60
24. McNeil BJ, Pauker SG, Sox HC, Tversky A (1982) On the eliciting of preferences for alternative therapies. N Eng J Med 306: 1259-1262
25. McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB (1995) Patient preferences for treatment of metastatic breast cancer: a study of women with early stage breast cancer. J Clin Oncol 13(4): 858-868
26. O'Connor AM (1998) Effects of framing and level of probability on patients' preferences for cancer chemotherapy. J Clin Epidemiol 42(2): 119-126
27. Quantin X, Riviere A, Daurus JP, Oliver P, Comte-Bardonnet M, Khial F, Marcillac I, Pujol JL (2000) Phase I-II study of high dose epirubicine plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose. Am J Clin Oncol 23(2): 192-196
28. Pierce P (1993) Deciding on breast cancer treatment: a description of decision behavior. Nurs Res 42: 22-29
29. Pierce P (1995) Michigan Assessment of Decision Style (MADS). Ann Arbor, MI: University of Michigan
30. Pruyn JFA, Borne van den HW, Reuver de RSM, Boer de MF, Bosman LJ, Pelkwijk ter MA, Jong de PC (1988) De locus of control schaal voor kankerpatienten. Tijdschr Social Gezondheidsz 66: 404-408
31. Porzsolt F (1993) Goals of palliative cancer therapy: scope of the problem. Cancer Treat Rev 19: 3-14
32. Porzsolt F, Tannock IF (1993) Goals of palliative cancer therapy. J Clin Oncol 11: 378-381
33. Ragnhammer P, Brorsson B, Nygren P, Glimelius B (2001) A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence. Acta Oncol 40: 391-411
34. Ramirez AJ, Towlson KE, Leaning MS, Richards MA, Rubens RD (1998) Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer 78(11): 1488-1494
35. Richards MA, Ramirez AJ, Degner LF, Fallowfield LJ, Maher EJ, Neuberger J (1995) Offering choice of treatment to patients with cancer. Eur J Cancer 31A(1): 112-116
36. Schiller JH, Adak S, Cella D, DeVore III RF, Johnson DH (2001) Topotecan versus obsercatin after cisplatin plus etoposide in extensive-stage small cell lung cancer. E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19(8): 2114-2122
37. Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced NSCLC descriptive study based on scripted interviews. BMJ 317: 771-775
38. Siminoff LA, Petting JH (1991) Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast cancer. Soc Sci Med 32(7): 813-818
39. Singer PA, Martin DK, Keiner M (1999) Quality end-of-life care. JAMA 28: 163-168
40. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, Downer SM (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300: 1458-1460
41. Stalmeier PF, Bezembinder TG (1999) The discrepancy between risky and riskless utilities: a matter of framing? Med Decision Making 19(4): 435-447
42. Stiggelbout AM, de Haes JCJM, Kiebert GM, Kievit J, Leer JW (1996) Tradeoffs between quality and quantity of life: development of the QQ Questionnaire for Cancer Patient Attitudes. Med Decision Making 16: 184-192
43. Stiggelbout AM, de Haes JCJM (2001) Patient preferences for cancer therapy: an overview of measurement approaches. J Clin Oncol 19: 220-230
44. Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF (1998) Responsiveness to change in health related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and trial specific module European Organization for Research and Treatment of Cancer. J Clin Oncol 51(2): 137-145
45. Sutherland HJ, Llewellyn-Thomas HA, Lockwood GA, Tritchler DL (1989) Cancer patients: their desire for information and participation in treatment decisions J Roy Soc Med 82: 260-263
46. Tannock IF (1998 Conventional cancer therapy: promise broken or promise delayed? Lancet 351(Suppl. II): 9-16
47. Thatcher N, Hopwood P, Anderson H (1997) Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer 33(Suppl 1): s8-s13
48. Unic IJ, Stalmeier PFM, Verhoef LCG, van Daal WAF (1998) Assessment of the time-tradeoff values for prophylactic mastectomy in women with a suspected genetic predisposition to breast cancer. Med Decision Making 18: 268-277
49. van Andel G, Kurth KH, Rietbroek RL, van de Velde-Muusers JA (2000) Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin plus medroxy progesterone acetate - is it feasible? Eur Urol 38(3): 259-264
50. Yellen SB, Cella DF (1995) Someone to live for: social wellbeing, parenthood status, and decision making in oncology. J Clin Oncol 13: 1255-1264
51. Watson M, Greer S, Pruyn J, Borne van den B (1990) Locus of control and adjustment to cancer. Psychol Rep 66: 39-48